BillionToOne Market Research Report
Company Overview
Name:
BillionToOne Inc.
Mission of the Company:
To remove the fear of the unknown by providing molecular diagnostics that are accurate, fast, and accessible.
Founding Information:
- Founded: 2016
- Founders: Oguzhan Atay, Ph.D., and David Tsao, Ph.D.
Key People in the Company:
- Oguzhan Atay, Ph.D. – Co-Founder, CEO, and Board Chair
- David Tsao, Ph.D. – Co-Founder, CTO, and Board Member
- Gary Palmer, MD, MBA, JD – Chief Medical Officer, Oncology
- Ross Taylor, MBA – Chief Financial Officer
- Shan Riku, MBA – Chief Product Officer
- Tom Lynch, JD – General Counsel
Headquarters:
Menlo Park, California, USA
Number of Employees:
As of April 2022, BillionToOne has more than 200 employees.
Revenue:
Reported over 100% growth in revenue year-over-year.
What is the Company Known For:
BillionToOne is recognized for its proprietary molecular counting technology that enables disease detection at single molecule sensitivity, improving prenatal screening and liquid biopsy.
Products
UNITY Screen™
- Description: A non-invasive prenatal test (NIPT) combining fetal screening for aneuploidies and recessive conditions from a single maternal blood draw.
- Key Features:
- Detects fetal risk for aneuploidies, recessive conditions, and fetal antigens.
- Only requires a maternal blood draw at 10+ weeks of pregnancy.
- Does not require a paternal sample, supporting equitable care.
Northstar Select™
- Description: A liquid biopsy test for determining the most appropriate first-line therapy in oncology.
- Key Features:
- Provides a prioritized list of mutations present in the tumor.
- Offers broad genomic coverage with a low limit of detection.
Northstar Response™
- Description: A liquid biopsy test to monitor if cancer therapy is working by assessing changes in tumor burden.
- Key Features:
- Employs a multi-cancer methylation signature.
- Quantifies changes in tumor burden enabled by molecular counting technology.
Recent Developments
New Product Launches:
- UNITY Screen™ enhancements for prenatal care and more comprehensive screenings.
- Northstar Select™ and Northstar Response™ are now available for clinical use in oncology.
Added Features:
- UNITY Fetal Antigen NIPT transforms care in maternity health deserts by enabling early detection without paternal samples.
- Northstar Select™ now offers enhanced genomic profiling capability.
New Partnerships:
- BillionToOne established a global collaboration with Johnson & Johnson for UNITY Fetal Antigen™ Clinical Trial Assay in a Phase 3 clinical trial.
Financial Achievements:
- Series D Funding: Raised $130 million in June 2024 with a valuation exceeding $1 billion.
- Secured $140 million non-dilutive financing with Oberland Capital as of September 2024.
Recognitions:
- Named Diagnostics Company of the Year by BioTech Breakthrough Awards.
Revenue Growth:
- Reported over 100% growth in revenue year-over-year as of January 28, 2025.
Executive Appointments:
- Announced three executive appointments amid rapid growth in November 2024.
Publications and Research
Notable Publications:
- UNITY Fetal Antigen Clinical Outcomes published in Obstetrics and Gynecology.
- Performance Characteristics of a Next Generation Sequencing-Based cfDNA Assay for common aneuploidies published in Annals of Gynecology and Obstetrics Research.
Events and Conferences:
BillionToOne participated in various industry conferences such as the JP Morgan Healthcare Conference and the Green Room Podcast, contributing to ongoing industry discussions and showcasing their technological advances.
This report highlights the extensive and focused advances by BillionToOne in molecular diagnostics, particularly in the areas of prenatal screening and oncology, thereby positioning itself as a leader in precision diagnostics.
